The Science Behind Immunab Research
Immunab Research is advancing a new generation of Chimeric Antigen Receptor (CAR) T-cell therapies to fight cancer. CAR-T cells are engineered immune cells designed to recognize and destroy tumor cells by targeting specific proteins on their surface. While CAR-T has already transformed the treatment of blood cancers, solid tumors remain a major challenge. Immunab is tackling this frontier with two innovative, patent-protected technologies
Welcome to Immunab Research
The first technology, developed through a Canadian Institutes of Health Research–funded program, involves novel CAR designs originally focused on viral targets and now expanded to solid tumor applications. Supported by PCT patent filing WO 2023/021494 A1, this platform was pioneered by Dr. Christopher Rudd, an internationally recognized immunologist, and transferred under exclusive rights for development by Immunab.
Both technologies are now under active development at Immunab’s laboratories at adMare BioInnovations in Montreal, where Dr. Rudd and the Immunab team are building on promising preclinical evidence. In mouse models, these therapies have demonstrated superior ability to clear solid tumors compared to existing CAR-T therapies currently in the clinic.
Our second innovation targets a newly discovered protein regulator called Rasal1, which normally acts as a “brake” inside immune cells. By downregulating Rasal1 in CAR-T cells, Immunab has shown a dramatic increase in tumor clearance in preclinical models. This approach—covered by a second provisional patent—enhances the power of CAR-T therapy without introducing added toxicity, offering the potential for safer and more durable cancer treatments.
Immunab’s mission is simple: to translate breakthrough science into transformative therapies for patients with solid cancers. With strong intellectual property, cutting-edge facilities, and a team anchored by world-class immunology expertise, Immunab is positioned to become a leader in the next wave of CAR-T innovation.
A Dedicated Team
Dr. Christopher E. Rudd Ph.D., D.Sc., FRCPath, FMedSci – Founder & CEO
Award-winning, leading
researcher and professor in
immunotherapy. Professor at Université de Montréal and McGill University. Formerly affiliated with HarvardMedical School, Dana-Farber Cancer Institute, and the University of Cambridge (UK). Currently serves as the Director of the Cellular Signaling in Immunotherapy Research Unit at the HMR Research Center.
Eric de Gheldere - Managing Partner
Seasoned entrepreneur focused
on developing new companies
in life science and AI.
Dr. Fatemeh Yousefi - Research Associate
Accelerating Lab-to-Patient Treatment With Tailored CAR-T
Therapy
Designer Anti-Tumor Cells
Engineered to Recognize and Kill Tumors
A Safer Double Kill Attack on Tumor
Cancer is the world’s scond leading killer and the fastest-growing cause of death globally….